Ekso Bionics Holdings, Inc.

Greetings. Welcome to the ExoBionics second quarter 2021 financial results call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Matt Steinberg. Thank you. You may begin.

Thank you, operator. And thank you all for participating in today's call. Joining me from Exobionics are Jack Purak, President and Chief Executive Officer, Jack Len, Chief Financial Officer, and Bill Shaw, Chief Commercial Officer. Earlier today, Exobionics released financial results for the quarter ended June 30th, 2021. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including our future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. EXO disclaims any intention or obligation, except as required by law, to update or revise any financial or operational projections, our regulatory outlook, or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the broadcast today, July 29, 2021. I will now turn the call over to Jack Purak. Thanks, Matt, and thanks, everybody, for joining today.

We are pleased with the progress we made in the second quarter, which extended our solid start to 2021. During the quarter, we focused on building momentum with network operators and driving adoption of our subscription access models. Through these combined initiatives, we closed several multi-unit orders with top network operators globally. During the quarter, we recorded 20 XONR bookings, including 11 subscription bookings worldwide, both up from the first quarter. For the second quarter, we generated revenue of $2.2 million, up 16% from the first quarter. We are pleased that onsite demos are now back to pre-COVID levels as business conditions gradually improve. However, we are closely monitoring the very fluid landscape as the spread of COVID variants may potentially affect in-person interactions. Our ability to be flexible with our virtual sewing solutions and online educational webinars has us well prepared in the event of any sudden changes. On the industrial side, we are pleased to see a continued high level of customer interest and an increase in onsite evaluations and pilot programs. As I will discuss later, we are building awareness for Evo, which has generated positive feedback to date in several market verticals. Financially, we achieved solid gross margins as we continue to see the benefits of the cost initiatives we put in place last year. Now, I would like to turn the call over to Bill for an update on our medical segment and global commercial strategy.